Oasmia Initiating Phase II Study of Drug in Canine Lymphoma
Oasmia Pharmaceutical AB announced today that the company has initiated a clinical Phase II study of Doxophos Vet for the treatment of canine lymphoma.
This study will be conducted at two clinics in the United States and Sweden, respectively. It includes five dose cycles of Doxophos Vet, which contains the active ingredient in doxorubicin, a commonly used chemotherapy drug in humans.
The primary endpoint is the response rate in the treated dogs after five cycles.
CEO of Oasmia said study is an important step for vetrinarians
”The continued development of this unique pharmaceutical is an important step for us, and for all dog owners," said Julian Aleksov, CEO of Oasmia. "It is also an important step for veterinarians, since Doxophos Vet will be a treatment for dogs evaluated on dogs."
”With Doxophos Vet, we can have a pharmaceutical which is specialized for dogs with this very common type of cancer," said Aleksoy.
Currently there is no specialized veterinary treatment for canine lymphoma.
Source: Globe News Wire
Photo by Luke Ma
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
